Progress in Cancer Immunotherapies

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Immunology".

Deadline for manuscript submissions: 25 December 2024 | Viewed by 1518

Special Issue Editors


E-Mail Website
Guest Editor
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Interests: immunotherapy; immune receptor signaling; tumor microenvironment; cancer metastasis

E-Mail Website
Guest Editor
Garvan Institute of Medical Research, Sydney, Australia
Interests: computational biology; cancer genetics/genomics and epigenetics/epigenomics; machine learning

Special Issue Information

Dear Colleagues,

In recent years, the field of cancer immunotherapy has undergone a transformative evolution, emerging as a beacon of hope in the fight against cancer. This Special Issue "Progress in Cancer Immunotherapies" within the journal Cells embarks on a focused exploration of this dynamic domain, seeking to encapsulate the relentless advancements that have propelled immunotherapy to the forefront of oncological research.

Immunotherapy has redefined the treatment paradigm by harnessing the inherent capabilities of the immune system to recognize and eliminate cancer cells. From immune checkpoint inhibitors to adoptive cell therapies, the repertoire of immunotherapeutic strategies continues to expand, presenting unprecedented opportunities to revolutionize cancer care. This Special Issue aims to delineate the contours of this rapidly evolving landscape, concentrating on key aspects such as the development of novel agents, breakthroughs in understanding the intricate interplay of immune cells within the tumour microenvironment, and strides in personalized immunotherapy approaches.

By delving into the nuances of these pivotal areas, this Special Issue endeavours to serve as a compass, guiding researchers, clinicians, and stakeholders through the intricate maze of cancer immunotherapies. As we navigate this exciting frontier, the collective insights presented within this compilation strive to accelerate the translation of groundbreaking discoveries into tangible clinical outcomes, fostering a deeper understanding of the challenges and promises inherent in the pursuit of conquering cancer through the prism of immunological innovation.

Dr. Van Ngu Trinh
Dr. Phuc Loi Luu
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer immunotherapy
  • immune checkpoint inhibitors
  • personalized immunotherapy
  • tumor microenvironment
  • biomarkers in immunotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

22 pages, 3365 KiB  
Review
Emerging Role of Extracellular pH in Tumor Microenvironment as a Therapeutic Target for Cancer Immunotherapy
by Md Ataur Rahman, Mahesh Kumar Yadab and Meser M. Ali
Cells 2024, 13(22), 1924; https://doi.org/10.3390/cells13221924 - 20 Nov 2024
Viewed by 338
Abstract
Identifying definitive biomarkers that predict clinical response and resistance to immunotherapy remains a critical challenge. One emerging factor is extracellular acidosis in the tumor microenvironment (TME), which significantly impairs immune cell function and contributes to immunotherapy failure. However, acidic conditions in the TME [...] Read more.
Identifying definitive biomarkers that predict clinical response and resistance to immunotherapy remains a critical challenge. One emerging factor is extracellular acidosis in the tumor microenvironment (TME), which significantly impairs immune cell function and contributes to immunotherapy failure. However, acidic conditions in the TME disrupt the interaction between cancer and immune cells, driving tumor-infiltrating T cells and NK cells into an inactivated, anergic state. Simultaneously, acidosis promotes the recruitment and activation of immunosuppressive cells, such as myeloid-derived suppressor cells and regulatory T cells (Tregs). Notably, tumor acidity enhances exosome release from Tregs, further amplifying immunosuppression. Tumor acidity thus acts as a “protective shield,” neutralizing anti-tumor immune responses and transforming immune cells into pro-tumor allies. Therefore, targeting lactate metabolism has emerged as a promising strategy to overcome this barrier, with approaches including buffer agents to neutralize acidic pH and inhibitors to block lactate production or transport, thereby restoring immune cell efficacy in the TME. Recent discoveries have identified genes involved in extracellular pH (pHe) regulation, presenting new therapeutic targets. Moreover, ongoing research aims to elucidate the molecular mechanisms driving extracellular acidification and to develop treatments that modulate pH levels to enhance immunotherapy outcomes. Additionally, future clinical studies are crucial to validate the safety and efficacy of pHe-targeted therapies in cancer patients. Thus, this review explores the regulation of pHe in the TME and its potential role in improving cancer immunotherapy. Full article
(This article belongs to the Special Issue Progress in Cancer Immunotherapies)
Show Figures

Figure 1

Back to TopTop